Tennessee is currently home to 1990 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults
Recruiting
The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the virus that causes COVID-19) and influenza. Participants enrolled in this trial will be healthy adults, 50 years of age or older.
Gender:
All
Ages:
50 years and above
Trial Updated:
02/20/2024
Locations: Clinical Research Associates Inc, Nashville, Tennessee
Conditions: Influenza, Human, SARS-CoV-2 Infection, COVID-19
Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents
Recruiting
The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents. The study duration will be up to 12 months for all participants.
Gender:
All
Ages:
Between 10 years and 25 years
Trial Updated:
02/20/2024
Locations: Pediatric Clinical Trials Tullahoma Site Number : 8400020, Tullahoma, Tennessee
Conditions: Meningococcal Infection, Healthy Volunteers
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Recruiting
This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Amulet™ ADVANCE LAA
Recruiting
This is a prospective, multicenter, observational study intended to characterize real-world outcomes on the commercially available Amulet device in the United States. The study will enroll approximately 1000 subjects at up to 50 US clinical sites. Subjects will be followed through 24 months in accordance with each site's standard care practices.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Vanderbilt Heart & Vascular Institute, Nashville, Tennessee
Conditions: Atrial Fibrillation, Stroke, Bleeding
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Recruiting
This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemotherapy, individually called a "study drug" or collectively called "study drugs". 'Investigational' means that the study drug is not approved for use outside of this study by any Health Authority. Examples of chemotherapy drugs include the following: Paclitaxel plus carboplatin, and Pemetrexed plus cisplatin. The study is being conducted in patients who... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Thompson Cancer Survival Center (TCSC) Downtown, Knoxville, Tennessee
Conditions: Non-small Cell Lung Cancer
A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis
Recruiting
The primary objectives are to investigate the safety and tolerability of BIIB091 monotherapy in participants with relapsing multiple sclerosis (RMS) (Part 1), and to evaluate the effects of BIIB091 combination therapy with Diroximel Fumarate (DRF) compared with the DRF monotherapy arm, on the key Magnetic Resonance Imaging (MRI) measure of active Central Nervous System (CNS) inflammation (Part 2). The secondary objectives are to evaluate the effects of BIIB091 monotherapy on the MRI measures of... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
02/20/2024
Locations: Neurology Clinic, PC, Cordova, Tennessee
Conditions: Relapsing Forms of Multiple Sclerosis
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Recruiting
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aim of the study is to see how effective the combination of fianlimab and cemiplimab is in treating advanced NSCLC, in comparison with cemiplimab by itself. The study is looking... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Thompson Cancer Survival Center (TCSC ) - Downtown, Knoxville, Tennessee
Conditions: Advanced Non-Small Cell Lung Cancer
A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face
Recruiting
The purpose of this study is to investigate the efficacy and safety of NT 201 injections in the treatment of enlarged pores and excessive sebum production in the face.
Gender:
All
Ages:
Between 21 years and 45 years
Trial Updated:
02/20/2024
Locations: Merz Investigation Site #001097, Nashville, Tennessee
Conditions: Enlarged Pores, Sebum Production
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)
Recruiting
The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) for 52 weeks in combination with prednisone tapered over 24 weeks in adult participants with PMR who have recently relapsed.
Gender:
All
Ages:
50 years and above
Trial Updated:
02/20/2024
Locations: West Tennessee Research Institute, Jackson, Tennessee
Conditions: Polymyalgia Rheumatica
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
Recruiting
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
All
Ages:
12 years and above
Trial Updated:
02/20/2024
Locations: Ramesh C Gupta MD Memphis TN, Memphis, Tennessee
Conditions: Systemic Lupus Erythematosus
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Recruiting
Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib at 2 dose levels (160 mg once daily [QD] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatment with furmonert... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Arrivent Investigative Site, Memphis, Tennessee
Conditions: Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
Recruiting
A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
02/20/2024
Locations: Research Site, Nashville, Tennessee
Conditions: Eosinophilic Esophagitis